Humanin Nanoparticles for Reducing Pathological Factors Characteristic of Age-Related Macular Degeneration.
Solanki. Aum A; Smalling. Rudy R; Parola. Abraham H AH; Nathan. Ilana I; Kasher. Roni R; Pathak. Yashwant Y; Sutariya. Vijaykumar V
Key Findings
- AGA‑HNG can be encapsulated in chitosan nanoparticles about 346 nm in size
- Nanoparticle‑bound AGA‑HNG retains anti‑VEGF and anti‑apoptotic activity similar to free peptide
- The nanoparticle formulation shows better stability, controlled release, and lower cellular toxicity than the free peptide
Practical Outcomes
- At this point the findings are not ready for DIY use or clinical protocols, but they suggest that humanin‑based treatments could eventually be delivered to the eye with fewer side effects. For biohackers, the study highlights the potential of peptide‑nanoparticle combos for anti‑aging eye health, though more animal and human data are needed before any self‑experimentation.
Summary
Scientists made a stronger version of the brain peptide humanin (called AGA‑HNG) and packed it into tiny chitosan particles. In lab tests on eye‑cell cultures, these particles lowered the harmful VEGF protein and protected cells from oxidative death, while being less toxic and releasing the drug more steadily than the plain peptide. The work shows the concept works, but it’s still early‑stage and only tested in dishes, not in people.
Abstract
Humanin is a novel neuronal peptide that has displayed potential in the treatment of Alzheimer's Disease through the suppression of inflammatory IL-6 cytokine receptors. Such receptors are found throughout the body, including the eye, suggesting its other potential applications. Age-related Macular Degeneration (AMD) is the leading cause of blindness in the developing world. There is no cure for this disease, and current treatments have several negative side effects associated with them, making finding other treatment options desirable. In this study, the potential applications in treating AMD for a more potent humanin derivative, AGA-HNG, were studied. AGA-HNG was synthesized and encapsulated in chitosan Nanoparticles (NPs), which were then characterized for their size, Encapsulation Efficiency (EE), and drug release. Their ability to suppress VEGF secretion and protect against oxidative apoptosis was studied in vitro using ARPE-19 cells. The chitosan NPs exhibited similar anti-VEGF properties and oxidative protection as the free protein while exhibiting superior pharmaceutical characteristics including biocompatibility and drug release. Drug-loaded NPs exhibited a radius of 346nm with desirable pharmacokinetic properties including a stable surface charge (19.5 ± 3.7 mV) and steady drug release capacity. AGA-HNG showed great promise in mediating apoptosis in hypoxic cells. They were also able to significantly reduce VEGF expression in vitro with reduced cellular toxicity compared to the free drug. The ability of this drug delivery system to reduce retinal apoptosis with desirable pharmacokinetic and biocompatible properties makes this a promising therapeutic option for AMD.
Study Information
pubmed
2019
2019-02-28T00:00:00.000Z
10.2174/1567201815666181031163111
14
42